中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 7
Jul.  2018
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2018  >  34(7): 1456-1461

Clinical features of patients with Barcelona Clinic Liver Cancer stage C primary liver cancer and related prognostic factors: An analysis of 140 cases

DOI: 10.3969/j.issn.1001-5256.2018.07.019

  • Department of Medical Oncology, Beijing Ditan Hospital, Capital Medical University

Research funding:

 

  • Received Date: 2017-12-11
  • Published Date: 2018-07-20
    Abstract
  • Objective To investigate the clinical features of patients with Barcelona Clinic Liver Cancer ( BCLC) stage C primary liver cancer ( PLC) and related prognostic factors. Methods A retrospective analysis was performed for the clinical data of 140 patients with BCLC stage C PLC who were admitted to Beijing Ditan Hospital, Capital Medical University, from October 2008 to December 2015. The Kaplan-Meier method was used for survival analysis, and the log-rank test was used for univariate analysis. The multivariate Cox proportional hazards model was used to analyze prognostic factors according to forward stepwise regression based on maximum likelihood estimation. Results Most of the 140 patients were male, and the male/female ratio was 6∶ 1. The three most common initial symptoms of PLC were abdominal pain or liver area pain, weakness, and abdominal distension. The median survival time was 6 months, and the median follow-up time was 10 months ( 1-80 months) . The 1-year survival rate of these patients was 22. 14%. The univariate analysis showed that Child-Pugh class, the type of portal vein tumor thrombus, tumor number, tumor morphology, tumor diameter, aspartate aminotransferase/alanine aminotransferase ( AST/ALT) ratio, and use or non-use of transcatheter arterial chemoembolization ( TACE) were associated with prognosis ( χ2= 6. 215, 19. 609, 8. 849, 11. 122, 11. 571, 7. 438, 30. 511, and 10. 690, all P < 0. 05) . The multivariate analysis showed that Child-Pugh class ( odds ratio [OR]= 1. 524, 95% confidence interval [CI]: 1. 011-2. 297, P = 0. 044) , tumor diameter ( OR = 1. 803, 95%CI: 1. 097-2. 964, P = 0. 020) , and AST/ALT ratio ( OR = 1. 769, 95% CI: 1. 301-2. 406, P < 0. 001) were independent risk factors for the prognosis of advanced PLC, while the use of TACE was a protective factor ( OR = 0. 598, 95% CI: 0. 363-0. 985, P = 0. 043) .Conclusion Advanced PLC has poor prognosis and short median survival time. A more accurate survival benefit analysis should be performed based on adverse prognostic factors to guide the selection of therapeutic paradigms in clinical practice. Increased AST/ALT ratio should also be taken seriously.

     

    • FullText(HTML)
    • References(23)
  • [1]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
    [2]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
    [3]LENCIONI R, LLOVET JM.Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis, 2010, 30 (1) :52-60.
    [4]HSU C, SHEN YC, CHENG CC, et al.Geographic difference in survival outcome for advanced hepatocellular carcinoma:Implications on future clinical trial design[J].Contemp Clin Trials, 2010, 31 (1) :55-61.
    [5]TINKLE CL, HAAS-KOGAN D.Hepatocellular carcinoma:Natural history, current management, and emerging tools[J].Biologics, 2012, 6:207-219.
    [6]ZHAO RR, DENG YD, YUAN H.Epidemiological and clinical features of primary liver cancer:An analysis of 236 patients[J].J Clin Hepatol, 2016, 32 (8) :1538-1542. (in Chinese) 赵荣荣, 邓永东, 袁宏.236例原发性肝癌患者流行病学及临床特点分析[J].临床肝胆病杂志, 2016, 32 (8) :1538-1542.
    [7]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.
    [8] CENTER MM, JEMAL A.International trends in liver cancer incidence rates[J].Cancer Epidemiol Biomarkers Prev, 2011, 20 (11) :2362-2368.
    [9]de MARIA N, MANNO M, VILLA E.Sex hormones and liver cancer[J].Mol Cell Endocrinol, 2002, 193 (1-2) :59-63.
    [10] MARRERO JA, KUDO M, BRONOWICKI JP.The challenge of prognosis and staging for hepatocellular carcinoma[J].Oncologist, 2010, 15 Suppl 4:23-33.
    [11]LIU JY, JIN J, GUAN S, et al.The effect of hepatic function status on the survival time in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization[J].J Intervent Radiol, 2013, 22 (3) :247-250. (in Chinese) 刘纪营, 金洁, 管生, 等.肝功能状态对晚期肝癌介入治疗生存期的影响[J].介入放射学杂志, 2013, 22 (3) :247-250.
    [12] XUE TC, XIE XY, ZHANG L, et al.Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus:A meta-analysis[J].BMC Gastroenterol, 2013, 13:60.
    [13]RAOUL JL, BRUIX J, GRETEN TF, et al.Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function:SHARP trial subanalyses[J].J Hepatol, 2012, 56 (5) :1080-1088.
    [14]CHENG AL, GUAN Z, CHEN Z, et al.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:Subset analyses of the phase III Sorafenib AsiaPacific trial[J].Eur J Cancer, 2012, 48 (10) :1452-1465.
    [15]WU ZY.Risk factors of prognosis in patients with advanced liver cancer after transcather arterial chemoembolization[J].J Pract Hepatol, 2015, 18 (4) :427-429. (in Chinese) 吴照宇.中、晚期肝癌介入治疗预后的影响因素分析[J].实用肝脏病杂志, 2015, 18 (4) :427-429.
    [16]NIU ZJ, MA YL, KANG P, et al.Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:Using a new classification[J].Med Oncol, 2012, 29 (4) :2992-2997.
    [17]NISHIKAWA H, OSAKI Y, KITA R, et al.Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma[J].Oncol Rep, 2014, 31 (1) :65-72.
    [18] XIANG Y, YANG T, PANG BY, et al.The progress and prospects of putative biomarkers for liver cancer stem cells in hepatocellular carcinoma[J].Stem Cells Int, 2016, 2016:7614971.
    [19] MORIMOTO M, NUMATA K, MORIYA S, et al.Inflammationbased prognostic score for hepatocellular carcinoma patients on sorafenib treatment[J].Anticancer Res, 2012, 32 (2) :619-623.
    [20]CHANGCHIEN CS, CHEN CL, YEN YH, et al.Analysis of 6381hepatocellular carcinoma patients in southern Taiwan:Prognostic features, treatment outcome, and survival[J].J Gastroenterol, 2008, 43 (2) :159-170.
    [21]CHAO Y, CHUNG YH, HAN G, et al.The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma:Final results of the START trial[J].Int J Cancer, 2015, 136 (6) :1458-1467.
    [22]FU QH, ZHANG Q, BAI XL, et al.Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma:A systematic review and meta-analysis[J].J Cancer Res Clin Oncol, 2014, 140 (8) :1429-1440.
    [23] BRUIX J, CHENG AL, MEINHARDT G, et al.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma:Analysis of two phase III studies[J].J Hepatol, 2017, 67 (5) :999-1008.
    • Relative Articles

  • Relative Articles

    [1]Yu ZHANG, Yongfeng YANG. Thinking of the pathological diagnosis of unexplained liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 498-503. doi: 10.3969/j.issn.1001-5256.2023.03.003
    [2]Xixuan WANG, Liangzi DING, Yang CHENG, Hao HAN, Jian YANG, Jiangqiang XIAO, Yi WANG, Ming ZHANG, Feng ZHANG, Yuzheng ZHUGE. Value of liver stiffness measured by acoustic radiation force impulse in diagnosis of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2022, 38(11): 2488-2492. doi: 10.3969/j.issn.1001-5256.2022.11.010
    [3]Jialing ZHOU, Bingqiong WANG, Yameng SUN, Tongtong MENG, Shanshan WU, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA, Xiaoning WU. Application value of liver stiffness measurement-to-platelet ratio index score in diagnosis of hepatitis B liver fibrosis and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1529-1533. doi: 10.3969/j.issn.1001-5256.2022.07.014
    [4]Zhongjie YU, Wenxia ZHAO, Leixin FENG, Hanxiao WANG, Jianpeng LIU. Value of five noninvasive diagnostic methods for liver cirrhosis in diagnosis of traditional Chinese medicine syndrome types in patients with compensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(1): 104-109. doi: 10.3969/j.issn.1001-5256.2022.01.016
    [5]Yajie XU, Wenzheng YOU, Wanlei REN, Quanhe LONG, Xiangjun JIANG, Doudou HU. Application of pathological indicators based on liver biopsy in the diagnosis of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2021, 37(12): 2935-2938. doi: 10.3969/j.issn.1001-5256.2021.12.042
    [6]Yu WANG, Min WANG, Guanhua ZHANG, Fuliang HE, Xiaojuan OU, Jidong JIA. Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 17-21. doi: 10.3969/j.issn.1001-5256.2021.01.004
    [7]NIU XingJie, LIU ZhiHui, CUI FengMei, LIU YaoMin, WANG YanFei, ZHANG GuoMin, LIU JinXia. Value of peripheral blood long non-coding RNA-LET in the diagnosis of chronic hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2709-2713. doi: 10.3969/j.issn.1001-5256.2020.12.014
    [8]Zhou ShengYun, Duan ZhiHui. Noninvasive diagnosis of esophageal varices in liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1842-1846. doi: 10.3969/j.issn.1001-5256.2020.08.036
    [9]Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. Journal of Clinical Hepatology, 2019, 35(10): 2163-2172. doi: 10.3969/j.issn.1001-5256.2019.10.007
    [10]Li JiaNa, Zheng RuiQi, Li Na, Hu YuLin. The biological characteristics of GP73 and its value in the diagnosis of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1361-1364. doi: 10.3969/j.issn.1001-5256.2019.06.040
    [11]Zhang YaNan, Jiang Chang, Xu Ying, Gao YanHang. Early diagnosis of spontaneous bacterial peritonitis in liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1851-1853. doi: 10.3969/j.issn.1001-5256.2019.08.045
    [12]Liu HaiFeng, Xu YongSheng, Zhang Yue, Zhao XiaoJu, Liu Zhao, Li JinKui, Yan RuiFeng, Xu Kai, Lei JunQiang. Value of magnetic resonance morphological imaging in the diagnosis and differentiation of post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2587-2591. doi: 10.3969/j.issn.1001-5256.2018.12.016
    [13]Yang ErNa, Cao WuKui. Research advances in noninvasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2209-2213. doi: 10.3969/j.issn.1001-5256.2017.11.035
    [14]Du JingHua, Nan YueMin. Novel molecular diagnostic markers for liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 445-450. doi: 10.3969/j.issn.1001-5256.2017.03.009
    [15]Zhang Hui, Jia Lei, Lu: Dong, Xu YouQing. Value of serum cancer antigen12-5 level in diagnosis of peritoneal effusion in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2118-2120. doi: 10.3969/j.issn.1001-5256.2016.11.022
    [16]Deng Han, Qi XingShun, Zhu Qiang, Guo XiaoZhong. Alternative methods for diagnosis of esophageal varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1468-1473. doi: 10.3969/j.issn.1001-5256.2016.08.007
    [17]Zhao Wei. Clinical significance of plasma  and urine neutrophil gelatinase-associated lipocalin levels in diagnosis of acute kindney injury  in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1874-1877. doi: 10.3969/j.issn.1001-5256.2015.11.025
    [18]Wang Shuai, Hu DaRong. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Journal of Clinical Hepatology, 2015, 31(7): 1018-1022. doi: 10.3969/j.issn.1001-5256.2015.07.005
    [19]Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
    [20]Jia KeDong, Shi ShuXian, Ruan YouBing. Detection of sialic acid in hepatitis involved liver cirrhosis and its significance for HCC diagnosis[J]. Journal of Clinical Hepatology, 2005, 21(2): 101-103.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.5 %FULLTEXT: 4.5 %META: 91.7 %META: 91.7 %PDF: 3.8 %PDF: 3.8 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 11.1 %其他: 11.1 %其他: 1.2 %其他: 1.2 %Austell: 0.2 %Austell: 0.2 %Baden: 0.2 %Baden: 0.2 %Canton: 0.3 %Canton: 0.3 %Carrboro: 0.5 %Carrboro: 0.5 %Central District: 0.5 %Central District: 0.5 %Doylestown: 0.2 %Doylestown: 0.2 %Edinburg: 0.2 %Edinburg: 0.2 %India: 0.2 %India: 0.2 %Jamaica: 0.2 %Jamaica: 0.2 %New Zealand: 0.2 %New Zealand: 0.2 %Oakland: 0.2 %Oakland: 0.2 %Perth Amboy: 0.3 %Perth Amboy: 0.3 %Westbury: 0.3 %Westbury: 0.3 %上海: 3.8 %上海: 3.8 %丹佛: 0.2 %丹佛: 0.2 %亚特兰大: 0.2 %亚特兰大: 0.2 %亨德森: 0.2 %亨德森: 0.2 %休斯顿: 0.2 %休斯顿: 0.2 %佩尔城: 0.2 %佩尔城: 0.2 %兰州: 0.2 %兰州: 0.2 %凉山: 0.2 %凉山: 0.2 %加利福尼亚州: 0.2 %加利福尼亚州: 0.2 %北京: 6.1 %北京: 6.1 %南京: 0.5 %南京: 0.5 %南宁: 0.5 %南宁: 0.5 %卡尔加里: 0.2 %卡尔加里: 0.2 %卡罗尔顿: 0.2 %卡罗尔顿: 0.2 %厦门: 1.6 %厦门: 1.6 %吉林: 0.7 %吉林: 0.7 %哥伦布: 0.2 %哥伦布: 0.2 %天津: 0.9 %天津: 0.9 %奥卡拉: 0.2 %奥卡拉: 0.2 %宣城: 0.3 %宣城: 0.3 %密蘇里城: 1.0 %密蘇里城: 1.0 %山景城: 0.2 %山景城: 0.2 %布兰普顿: 0.3 %布兰普顿: 0.3 %帕克: 0.3 %帕克: 0.3 %广州: 0.2 %广州: 0.2 %开封: 0.2 %开封: 0.2 %开罗: 0.3 %开罗: 0.3 %张家口: 2.6 %张家口: 2.6 %意法半: 0.2 %意法半: 0.2 %成都: 0.7 %成都: 0.7 %拉雷多: 0.5 %拉雷多: 0.5 %昆明: 0.3 %昆明: 0.3 %朝阳: 0.2 %朝阳: 0.2 %杭州: 0.5 %杭州: 0.5 %桂林: 0.3 %桂林: 0.3 %森尼韦尔: 0.2 %森尼韦尔: 0.2 %武汉: 1.0 %武汉: 1.0 %沈阳: 0.3 %沈阳: 0.3 %泰勒: 0.2 %泰勒: 0.2 %洛杉矶: 0.2 %洛杉矶: 0.2 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.2 %济南: 0.2 %深圳: 0.2 %深圳: 0.2 %湛江: 0.2 %湛江: 0.2 %盖瑟斯堡: 0.3 %盖瑟斯堡: 0.3 %纽约: 0.3 %纽约: 0.3 %纽贝里: 0.2 %纽贝里: 0.2 %芒廷维尤: 26.9 %芒廷维尤: 26.9 %芝加哥: 0.9 %芝加哥: 0.9 %莫斯科: 1.0 %莫斯科: 1.0 %衡水: 0.5 %衡水: 0.5 %西宁: 22.4 %西宁: 22.4 %西安: 1.7 %西安: 1.7 %西雅图: 0.2 %西雅图: 0.2 %都伯林: 0.3 %都伯林: 0.3 %长春: 0.2 %长春: 0.2 %长沙: 1.0 %长沙: 1.0 %雅加达: 0.2 %雅加达: 0.2 %霍巴特: 0.3 %霍巴特: 0.3 %青岛: 0.7 %青岛: 0.7 %其他其他AustellBadenCantonCarrboroCentral DistrictDoylestownEdinburgIndiaJamaicaNew ZealandOaklandPerth AmboyWestbury上海丹佛亚特兰大亨德森休斯顿佩尔城兰州凉山加利福尼亚州北京南京南宁卡尔加里卡罗尔顿厦门吉林哥伦布天津奥卡拉宣城密蘇里城山景城布兰普顿帕克广州开封开罗张家口意法半成都拉雷多昆明朝阳杭州桂林森尼韦尔武汉沈阳泰勒洛杉矶洛阳济南深圳湛江盖瑟斯堡纽约纽贝里芒廷维尤芝加哥莫斯科衡水西宁西安西雅图都伯林长春长沙雅加达霍巴特青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2600) PDF downloads(337) Cited by(1)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2008]YesterdayPV[3584]TodayIP[1409]TodayPV[2759]Online[77]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return